2018 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

Welcome to another one of our Eberhard F. Mammen Award announcements. As noted many times previously, Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “ Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards ” in honor of Eberhard Mammen ([ Fig. 1 ]), and in recognition of his contribution to this field and to the journal that he founded and steered for over three decades.[ 1 ] [ 2 ] [ 3 ] These awards began in 2009, under two categories; the current award details and conditions are as follows: Fig. 1 Eberhard F. Mammen (1930–2008). Most Popular Article Awards : Awarded to the authors of the most popular articles published in Seminars in Thrombosis and Hemostasis . The awards are determined by the Editor-in-Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters to the Editor, and Editorials, and previous award winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Open Access” articles and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “Open Access” status for these articles thereafter. Young Investigator Awards : Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. In general, previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by vote by the senior editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Further details of the awards and the award winners are posted online (< https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077 >), and previous award winner announcements are also available in print.[ 4 ] [ 5 ] [ 6 ] [ 7 ] [ 8 ] [ 9 ] [ 10 ] [ 11 ] [ 12 ] [ 13 ] [ 14 ] [ 15 ] [ 16 ] [ 17 ] [ 18 ] The winners of the 2018 Eberhard F. Mammen Awards for the most popular articles from STH for the period of 2016 to 2017 inclusive were announced in an earlier issue of the journal.[ 18 ] It is therefore with great pleasure that we would like to announce the winners of the latest round of Young Investigator Awards. As mentioned earlier, the Young Investigator Awards represent winners of the best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. There are additional considerations given that the nominees' presentations are not always seen by all of the possible award nominators, being drawn from the editorial team of the journal. The latest winners are identified later and also listed in [ Table 1 ]. The latest awardees derived from a variety of meetings. Table 1 Latest (2018) Eberhard F. Mammen Young Investigator Award winners Awardee PhD status Current placement Presentations awarded Mark Schreuder, MSc Current PhD student Division of Thrombosis and Hemostasis in the Leiden University Medical Center, the Netherlands ASH 2017 USA Presentation: “Phe174-mutated human factor X as bypassing agent to the direct FXa inhibitors” James McFadyen, MBBS, FRACP, PhD Awarded PhD in 2016 Clinical hematologist in Melbourne, Victoria, Australia, working at the Alfred Hospital. He is also a research fellow at the Baker Heart and Diabetes Institute and a senior lecturer at Monash University, Faculty of Medicine, Nursing and Health Sciences 9th Haemostasis Update Meeting, 2018 Melbourne: “Role of platelets in haemostasis and thrombosis” David Rabbolini, BSc MBBCh (Witw.), FRACP FRCPA PhD Awarded PhD in 2018 Clinical hematologist at Lismore Base Hospital, NSW, Australia. Co-ordinator of a Sydney platelet co-operative group involving many hospitals 9th Haemostasis Update Meeting, 2018 Melbourne: “Platelet function testing” Janka Zolkova, MSc Current PhD student Department of Hematology and Transfusiology, Jessenius Faculty of Medicine, Martin, Slovakia XXVth Slovak-Czech conference on hemostasis and thrombosis, Martin, Slovakia, 2018: “Genetic background of von Willebrand disease.” Tomáš Bolek, MD Current PhD student Department of Internal Medicine I of Jessenius Faculty of Medicine in Martin, Slovakia XXVth Slovak-Czech conference on hemostasis and thrombosis, Martin, Slovakia, 2018: “Proton pump inhibition affects the dabigatran on-treatment levels in patients with atrial fibrillation” Fraser McCrae, BSc (Hons) Current PhD student Discovery and Translational Science Department, University of Leeds, UK 2nd Joint Meeting of the International Society of Fibrinolysis and Proteolysis and the Plasminogen Activation Workshop, Edinburgh, UK, 2018. “External blood clots are covered by a fibrin bio-film that protects against infection” Mark Schreuder ([ Fig. 2 ]) is currently a PhD student at the Division of Thrombosis and Hemostasis in the Leiden University Medical Center, The Netherlands. He obtained his degree as biomedical scientist in 2014 at the University of Utrecht and thereafter started his current research project, which focuses on the unique structural adaptations of the extremely procoagulant factor V and factor X proteins found in the venom of Australian elapid snakes. By uncovering the functional and molecular details of these adaptations, he aims to use these as a framework for the development of innovative bioengineered factor V and factor X therapeutic proteins for the treatment of hemophilia or direct oral anticoagulant (DOAC)-induced bleeding. Fig. 2 Young Investigator Award winner, Mark Schreuder. James McFadyen ([ Fig. 3 ]) is a clinical hematologist in Melbourne, Australia, currently working at the Alfred Hospital. He is also a research fellow at the Baker Heart and Diabetes Institute and a senior lecturer at the Faculty of Medicine, Nursing and Health Sciences, Monash University. After completion of his specialty training in hematology, Dr. McFadyen completed his PhD at the Australian Centre for Blood Diseases, Monash University, where he investigated the mechanisms of platelet hyperactivity in diabetes mellitus. Dr. McFadyen subsequently joined the Baker Heart and Diabetes Institute where his current work focuses on the development of novel, platelet-targeted therapeutics for the treatment of thrombotic, and thromboinflammatory diseases. Dr. McFadyen has been awarded several national and international awards and grants for his research and was recently awarded a prestigious National Health and Medical Research Council Early Career Fellowship. Fig. 3 Young Investigator Award winner, James McFadyen. David Rabbolini ([ Fig. 4 ]) was a PhD student at the time of his presentation, and is currently working as a hematologist at Lismore Base Hospital, NSW, Australia. Dr. Rabbolini obtained his medical degree from the University of the Witwatersrand, Johannesburg, South Africa. In 2006, he moved to Australia and successfully completed physician training (2009) and later joint training in laboratory and clinical hematology (2015). David's special interest is in thrombosis and hemostasis, and inherited platelet disorders in particular, and completed his PhD in this field in 2018. One of Dr. Rabbolini's current projects is the coordination of a Sydney platelet cooperative group whose aim is to improve the diagnosis of inherited platelet disorders in the region through the integration of comprehensive phenotypic and genetic analysis. Fig. 4 Young Investigator Award winner, David Rabbolini. Janka Žolková ([ Fig. 5 ]) is a current PhD student and the youngest of our award winners. Janka is currently placed at the Department of Hematology and Transfusiology, Jessenius Faculty of Medicine, Martin, Slovakia. She received her master degree in Biology and Chemistry in 2016 at the University of Pavol Jozef Safarik, Kosice, Slovakia. Her main interest is the genetic background of rare bleeding disorders, and studies this field in cooperation with National Center of Hemostasis and Thrombosis, Martin, Slovakia. She also participates in other research projects related to laboratory monitoring of platelet reactivity in patients on antiplatelet therapy and in investigating changes in expression of miRNAs in patients with high risk of thrombotic complications during pregnancy. Fig. 5 Young Investigator Award winner, Janka Žolková. Tomáš Bolek ([ Fig. 6 ]) is another current PhD student and also presently a clinical resident at the Department of Internal Medicine I of Jessenius Faculty of Medicine in Martin, Slovak Republic. He received his degree in medicine in 2015 and is completing a residency in internal medicine. He also currently works as a research fellow in internal medicine at the same department. As a researcher, he is interested in the field of DOAC therapy in patients with atrial fibrillation, in laboratory monitoring of this therapy, in drug interactions with DOACs, and in monitoring antiplatelet therapy in acute coronary syndromes and thrombosis, and in antithrombotic therapy of cardiovascular diseases. Fig. 6 Young Investigator Award winner, Tomáš Bolek. Fraser McCrae ([ Fig. 7 ]) is another PhD student, but positioned at the Discovery and Translational Science Department, University of Leeds, United Kingdom. He graduated in 2010 from the University of Leeds as a biomedical scientist, before taking up a role as a research associate investigating the role of intraluminal thrombi in the progression of abdominal aortic aneurysms. This led to a broader interest in coagulation, and he subsequently began his PhD exploring the role of the fibrin clots in cardiovascular disease and infection control. His current focus and research aims are to elucidate the role of fibrin films in infection control and wound healing. Fig. 7 Young Investigator Award winner, Fraser McCrae. All award winners were elated to hear that they had been selected to receive an Eberhard F. Mammen Young Investigator Award, and provided the following additional commentary: “I am extremely honored and deeply appreciate the nomination and distinction of the Eberhard F. Mammen Young Investigator Award. This award recognizes not only our research on bioengineered factor X variants as bypassing agent to the factor Xa-inhibiting DOACS, but also acknowledges the hard work and team effort that provided the foundation for this project. I would also like to take the opportunity to sincerely thank the Award Committee and of course my supervisors Prof. Pieter Reitsma and Dr. Mettine Bos.” - Mark Schreuder ([ Fig. 2 ]) “I am incredibly honored and humbled to be have been awarded an Eberhard F. Mammen Young Investigator Award. My research would not have been possible without the support and the wonderful mentorship I have been afforded to date. In particular, Professor Hatem Salem, Professor Shaun Jackson, Professor Karlheinz Peter and Associate Professor Huyen Tran, have been highly valued mentors who have all fostered my research and clinical interest in thrombosis.” - James McFadyen ([ Fig. 3 ]) “I am honored to be one of the recipients of the Eberhard F. Mammen Young Investigator Award and would like to thank Thieme and Seminars in Thrombosis and Hemostasis for continuing to support young investigators. It is every investigator's hope that their work is recognized and given a platform from which to share their ideas with their peers, and initiatives such as these make this possible.” - David Rabbolini ([ Fig. 4 ]) “I am delighted and honored to have received an Eberhard F. Mammen Young Investigator Award. I am so grateful for the appreciation of our research. I would like to thank my supervisors, professor Peter Kubisz and professor Jan Stasko for the opportunity to participate in this research. My thanks also goes to all my colleagues and to everyone else who participates in our research for their cooperation and support.” - Janka Žolková ([ Fig. 5 ]) “I am honored to have received an Eberhard F. Mammen Young Investigator Award. I deeply appreciate the recognition for my research and current projects. This award acknowledges a team effort and the hard work that has been put into these projects. Therefore, I would like to thank my colleagues from the Department of Internal Medicine I and National Centre of Thrombosis and Hemostasis in Martin for their enthusiasm for our research on new clinical problems connected with direct oral anticoagulation in patients with atrial fibrillation.” - Tomáš Bolek ([ Fig. 6 ]) “I feel honored to have been nominated and selected for the prestigious Eberhard F. Mammen Young Investigator Award. My presentation discussed the fascinating new findings from our laboratories of fibrin films that cover the surface of external blood clots and help prevent infection. I hope to be able to take this research forward to obtain a better understanding of these films and how they contribute to our wellbeing.” - Fraser McCrae ([ Fig. 7 ]) In keeping with previous editorials, I have again reviewed the Young Investigator awardees from previous years as well as the outcome of their subsequent submissions to STH, as summarized in [ Table 2 ]. I previously mentioned my personal gratification that most of the articles from earlier years have subsequently appeared in several annual top 100 listings.[ 9 ] [ 10 ] [ 12 ] [ 14 ] [ 15 ] [ 16 ] [ 18 ] Of further interest, one of these articles subsequently won one of the Most Popular Awards in 2014 (within the Open Access category) and based on the “most popular” 2012 to 2013 list.[ 10 ] [ 19 ] It is also motivating to observe that a few of the Young Investigator awardees were co-authors on other contributions to STH that were also listed in these most popular listings, including another 2014 Most Popular Award winner,[ 10 ] [ 20 ] and a 2018 Most Popular Award winner.[ 6 ] [ 21 ] [ 22 ] Table 2 Eberhard F. Mammen Young Investigator Award winners from previous years Awardee Year awarded Publication arising Willem M. Lijfering 2009 Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 2011;37(8):885–896 Salley Pels 2009 Pels SG. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost 2011;37(6):621–630 Adam Cuker 2010 Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost 2012;38(1):31–37 Giridhara Rao Jayandharan 2010 Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. Semin Thromb Hemost 2012;38(1):64–78 Timea Szanto 2010 Szántó T, Joutsi-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost 2012;38(1):55–63 Birgitta Salmela 2010 Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012;38(1):23–30 Pia Riittaa-Maria Siljander 2010 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 2012;38(1):102–113 Romaric Lacroix 2011 Lacroix R, Dignat-George F. Microparticles: new protagonists in pericellular and intravascular proteolysis. Semin Thromb Hemost 2013;39(1):33–39 Brad McEwen 2011 McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost 2013;39(1):25–32 Neil A. Goldenberg 2011 Bernard TJ, Armstrong-Wells J, Goldenberg NA. The institution-based prospective inception cohort study: design, implementation, and quality assurance in pediatric thrombosis and stroke research. Semin Thromb Hemost 2013;39(1):10–14 Vivien Chen 2011 Chen VM. Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange. Semin Thromb Hemost 2013;39(1):40–47 Joseph E. Italiano, Jr. 2011 Italiano JE Jr. Unraveling mechanisms that control platelet production. Semin Thromb Hemost 2013;39(1):15–24 Vivian Xiaoyan Du 2012/2013 Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the role of erythrocytes in thrombus formation. Semin Thromb Hemost 2014;40(1):72–80 Andrew Yee 2012/2013 Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost 2014;40(1):17–27 Sarah O'Brien 2012/2013 O'Brien SH. Contraception-related venous thromboembolism in adolescents. Semin Thromb Hemost 2014;40(1):66–71 Veronica Flood 2012/2013 Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost 2014;40(1):41–48 Julie Tange 2012/2013 Tange JI, Grill D, Koch CD, Ybabez RJ, Krekelberg BJ, Fylling KA, Wiese CR, Baumann NA, Block DR, Karon BS, Chen D, Pruthi RK. Local verification and assignment of mean normal prothrombin time and international sensitivity index values across various instruments: recent experience and outcome from North America. Semin Thromb Hemost 2014;40(1):115–120 Kent Chapman 2012/2013 Chapman K, Yuen S. Therapy for thrombotic thrombocytopenia purpura: past, present, and future. Semin Thromb Hemost 2014;40(1):34–40 Andreas Tiede 2014 Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia a: limitations, consequences, and challenges. Semin Thromb Hemost 2014;40(7):803–811 Wendy Lim 2014 Lim W. Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost 2014 S, M, M, F. of an on young with Semin Thromb Hemost 2014 as a laboratory monitoring during therapy in patients with hemophilia and Semin Thromb Hemost Maas 2014 C, R, L, de Groot PG, K, de S, Maas von Willebrand factor under for Semin Thromb Hemost 2014 R, A, M. of hemophilia factor and therapy. Semin Thromb Hemost 2015 J, M, T, Stasko J, Kubisz in the understanding of platelet syndrome. Semin Thromb Hemost 2015 L, T, B, M. of monitoring of antiplatelet therapy. Semin Thromb Hemost 2015 L, M, L, L, J, Stasko J, Kubisz of hemostasis and of anticoagulant in with risk of Semin Thromb Hemost 2015 thromboembolism in is Semin Thromb Hemost 2015 M, or of Semin Thromb Hemost M. 2015 S, Cannegieter for venous Semin Thromb Hemost 2016 S, James in von Willebrand understanding the clinical and Semin Thromb Hemost 2016 therapeutic in the treatment of hemophilia A. Semin Thromb Hemost 2016 K, K, H, S, S, S, L, D, S, L, to in with a of in to treatment in with antiphospholipid or Semin Thromb Hemost 2016 J, J, J, Baker R. as thrombosis and Semin Thromb Hemost 2016 oral in disease. Semin Thromb Hemost A. 2016 2017 based platelet function Semin Thromb Hemost 2017 2017 E, K, in arterial and venous Semin Thromb Hemost 2017 2017 J, or oral to bleeding risk a review of and Semin Thromb Hemost 2017 of special interest for the current of Young Investigator awardees is that of six were PhD at the time of their the was only awarded their PhD recently in These findings to the Young Investigator Award and I forward to their to These findings also that high have been for Young Investigator and I all awardees the best of to the by earlier award winners. It only to take the opportunity to thank previous Young Investigator awardees for their these have been well received by of this journal. I again the current Young Investigator awardees for their awards, and I forward to and monitoring the of their contributions published in this journal.